Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
- Address
- lock Available on a paid plan
Digestive System Diseases
The research team at Centrum Onkologii Ziemi Lubelskiej is conducting a series of studies on cancers of the gastrointestinal tract, aiming to improve survival and quality of life by testing novel targeted agents, immunotherapies, and diagnostic tools.
- Advanced gastric and gastro‑esophageal junction adenocarcinoma
- Esophageal squamous cell carcinoma
- Unresectable hepatocellular carcinoma
- Metastatic BRCA‑mutated pancreatic cancer
- Combination regimens with checkpoint inhibitors for digestive cancers
These trials bring together more than thirty investigators to evaluate new treatment options for patients across Lublin and the broader region.
Hemic and Lymphatic Diseases
A robust portfolio of hematology studies focuses on B‑cell malignancies and related disorders, with the goal of establishing more effective and tolerable therapies for both newly diagnosed and relapsed patients.
- Chronic lymphocytic leukemia / small lymphocytic lymphoma
- Mantle cell lymphoma and other aggressive B‑cell lymphomas
- Diffuse large B‑cell lymphoma, including high‑risk subgroups
- Multiple myeloma, including relapsed/refractory disease
- Acute myeloid leukemia with NPM1 mutation
Investigators are exploring BTK inhibitors, bispecific antibodies, and CAR‑T cell approaches to deepen responses and reduce disease burden.
Immune System Diseases
Clinical research at the site includes pioneering work on immune‑modulating therapies, ranging from checkpoint blockade to gene‑engineered cellular products, to enhance anti‑tumor immunity and address primary immunodeficiencies.
- Gene‑modified T‑cell therapy safety and long‑term efficacy
- PD‑1/PD‑L1 inhibitors such as pembrolizumab and durvalumab
- Combination immunotherapy with axitinib or tiragolumab
- Primary immunodeficiency disease diagnostics using advanced imaging
- Evaluation of novel immune checkpoint combinations in solid tumours
The programme seeks to define optimal regimens that balance potency with safety for patients with complex immune‑related conditions.
Neoplasms
A wide‑ranging oncology portfolio addresses major solid tumours, aiming to compare new targeted agents and combination strategies against standard chemotherapy to improve progression‑free and overall survival.
- Hormone‑receptor‑positive, HER2‑negative early and advanced breast cancer
- HER2‑positive metastatic breast cancer and neoadjuvant settings
- Ovarian cancer, including BRCA‑mutated and platinum‑sensitive disease
- Prostate cancer with advanced or metastatic disease
- Metastatic melanoma and head & neck squamous cell carcinoma
Through collaborations with international sponsors, the centre evaluates CDK4/6 inhibitors, antibody‑drug conjugates, and novel hormone therapies to set new standards of care.
Skin and Connective Tissue Diseases
Targeted investigations into cutaneous malignancies and related disorders are underway, focusing on innovative immunotherapies and precision medicines to improve outcomes for patients with skin‑derived cancers.
- Advanced melanoma, including brain‑metastatic cohorts
- Cutaneous T‑cell lymphoma and other skin‑related lymphoid neoplasms
- Evaluation of checkpoint inhibitors in skin cancer subtypes
- Biomarker‑driven studies for connective‑tissue tumor profiling
- Safety assessment of combination regimens involving targeted agents
The department leverages its expertise in dermatologic oncology to generate data that may translate into more personalized treatment pathways.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 134 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 128 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1AstraZeneca AB6active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
lock Showing 1 of 66 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy | Kartos Therapeutics Inc. | Phase IV | Not Recruiting | Aug 2023 | Jul 2024 |
IMP list
lock Showing 1 of 134 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 10 | Unknown | 2018-11-15 | 2025-04-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.